Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902758 · ClinicalTrials.gov registry record · Phase 2
Drug Combination on Exercise Performance at High Altitude
A Phase 2 study, sponsored by University of Montana.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01902758: Completed Phase 2 study, sponsored by University of Montana.
NCT01902758 is a Phase 2 study that has completed, run by University of Montana. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902758, a Phase 2 study, has completed, sponsored by University of Montana.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combination will reduce the symptoms of acute mountain sickness and improve exercise performance at high altitude compared to placebo.
Interventions
- DRUG placebo
- DRUG ambrisentan and theophylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
What the finished NCT01902758 record still lists
NCT01902758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01902758 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01902758 about?
NCT01902758 is a clinical study titled "Drug Combination on Exercise Performance at High Altitude". This study is being conducted to determine the effectiveness of using two FDA approved medications in concert to reduce the likelihood of sickness due to low oxygen levels and to reduce the decrement in physical performance at higher elevations. The investigators hypothesize that this drug combinati...
What is the current status of trial NCT01902758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2013-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01902758?
The interventions under investigation include: placebo (DRUG), ambrisentan and theophylline (DRUG).
Who is sponsoring clinical trial NCT01902758?
This trial is sponsored by University of Montana, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01902758's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia